Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. - Wikidata - wikimedia - TriplyDB

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

http://www.wikidata.org/entity/Q34621999

about

Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy Management of chemotherapy induced cardiomyopathy.Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials Anthracyclines: cardiotoxicity and its prevention.Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy.Doxorubicin and Dacarbazine (AD) Regimen for Soft Tissue Sarcomas State-of-the art therapy for gastrointestinal stromal tumors.Multimodality therapy for metastatic sarcomas confined to the lung.Primary leiomyosarcoma of gallbladder.A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.Anthracycline cardiotoxicity.Role of chemotherapy in the management of soft tissue sarcomas.Metastatic pleomorphic sarcoma to left atrium.Management of gastrointestinal stromal tumors.Chemotherapy-related cardiotoxicity.The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma.Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas.Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.Soft tissue sarcoma clinical practice guidelines in oncology.Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma.The duration of anthracycline infusion should be at least one hour in children with cancer: A clinical practice guideline.Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy.Infusional Mitoxantrone Plus Bolus Melphalan as a Stem Cell Transplant Conditioning Regimen for Multiple Myeloma

P2860

Q24240568-2B17A830-A81B-4419-8B93-16A61176339F Q24243810-92CF2B26-5C29-49F2-9E2B-9B0037863466 Q30461441-EBBDC954-5DF0-4672-9C34-21D50BB92778 Q33343936-8A6EAEA9-AD01-4BB2-A9B5-2FC848888B79 Q33619867-FB87763D-B19D-41BA-B416-81AFB0992577 Q33625243-DB35C623-4E07-4EE2-831F-5A3DAC7AF5B0 Q34506729-37FBB45D-A491-4B26-BD5A-7E51F6EA0246 Q35212176-4FF432ED-FA09-4563-BEE1-7FC3F0630EA9 Q36052217-AEFEB765-FD32-4F9F-B32D-0460F5880039 Q36156933-37268988-F840-425B-9253-F98428AF9D92 Q36424138-6E8B5F17-980B-4630-A0FE-15E63EFB400F Q36445552-2B205DEE-B191-495B-9CBB-6415E9F38D20 Q36612320-324BA06B-83AE-48AF-984B-E05460942DD8 Q36624983-E5FAC0AC-E4D8-419A-8D1F-664895EDE524 Q37687389-9856FDE0-5E0C-4986-913E-C0AC68049E71 Q37817765-680CD5E3-0398-41F8-A943-C4D487807F72 Q38081983-7F791734-02C4-472F-AE17-BF6069D05224 Q38088974-7DF3355A-5E07-43AF-B1FA-ADF2AD098251 Q38315670-27C8570F-3EC9-4BF0-ACAB-68C26C53845F Q38640435-553B081F-EC02-404A-95F1-65821A77468F Q38840133-43266113-9CEE-45E1-8F29-A78753E93F9A Q39743562-F63F8393-2477-418B-9E73-2C0C5ED6B4C0 Q42542953-5C6BC2C7-BB88-4742-9B9D-993EEBD6E3E3 Q42706690-37ABDF7A-B02B-4AB6-830C-8B439E6F3E53 Q44115428-6E0F1A98-319B-4F4D-8A62-6B409A79D6E2 Q44439070-40DB5E4E-CDBC-4D23-8AD9-C17779856E09 Q48114515-2F7EEE0B-D336-4949-854F-B03CDF8A2952 Q48151662-CAB1A84F-7B6D-4483-AA28-5DF92AB4FC0F Q54078609-D5F3A5FE-1814-4178-B308-4B28B0D8B0C5 Q55014795-A97EB221-672E-4804-83DF-3A279BF5AA9D

P2860

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

http://www.wikidata.org/entity/Q34621999

description

1991 nî lūn-bûn

@nan

1991 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1991 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

name

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@ast

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@en

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@nl

type

label

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@ast

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@en

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@nl

prefLabel

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@ast

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@en

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@nl

P1433

Q34621999-A58B6216-BA81-4415-AD8D-203AAB880FB6

P1476

Q34621999-2073E04E-CFF0-41EB-A0DF-FB3BD015B55F

P2093

Q34621999-61890D42-0D91-48FB-8CC9-91F542E3CDD2

Q34621999-787AC46D-B562-41B1-A32E-6A385697E97E

Q34621999-ABD457D9-AD19-4CB3-9807-3B757EE59917

Q34621999-B13EB1C0-0136-4D2C-82E8-7E98A6957771

Q34621999-C3506D94-4921-4345-A4CC-6A26232154F3

Q34621999-D79D8880-F27B-4D14-B786-3FDB60A38272

Q34621999-E35D6B88-0364-4E7E-A5AF-D714EB92EEAD

Q34621999-E9C04D1C-A0AA-4920-B669-9514AEC3AFF8

Q34621999-F1183E55-6A53-44D6-A930-6767A4A841A1

Q34621999-FC6C2752-731A-4899-930D-B1E8BDF59046

P304

Q34621999-DFC034FE-EAF4-4987-BD00-C2314B9572A1

P31

Q34621999-F196BB55-BC1C-4B43-A981-F977AB32C68A

P356

Q34621999-46CD777C-CC8D-40AA-B547-D3C8C0ADE0B8

P407

Q34621999-023EBA08-695F-420C-BB8E-E7331616667B

P433

Q34621999-E98BE6CE-5552-4775-A7EA-5CCD307D8E42

P478

Q34621999-E409DF13-061E-44C9-9EB4-64F50B2B9302

P577

Q34621999-4B583964-E1EC-4C82-83E0-90C5C8EB4878

P698

Q34621999-08F3EFAF-DB99-4B13-A5E3-4FEF61AF7393

P356

P1433

Journal of the National Cancer Institute

P1476

Phase III comparison of doxoru ...... outhwest Oncology Group study.

@en

P2093

Baker LH

http://www.w3.org/2001/XMLSchema#string

Balcerzak S

http://www.w3.org/2001/XMLSchema#string

Benjamin RS

http://www.w3.org/2001/XMLSchema#string

Bonnet JD

http://www.w3.org/2001/XMLSchema#string

Chapman R

http://www.w3.org/2001/XMLSchema#string

Fletcher WS

http://www.w3.org/2001/XMLSchema#string

Metch B

http://www.w3.org/2001/XMLSchema#string

Ryan J

http://www.w3.org/2001/XMLSchema#string

Weiss GR

http://www.w3.org/2001/XMLSchema#string

Zalupski M

http://www.w3.org/2001/XMLSchema#string

P304

926-932

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/83.13.926

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

1991-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2067035

http://www.w3.org/2001/XMLSchema#string